Patient baseline characteristics
| Characteristic . | Study population (n = 20) . |
|---|---|
| Age, median (range), y | 52.5 (36-66) |
| Sex | |
| Female | 7 (35%) |
| Male | 13 (65%) |
| Race | |
| White | 16 (80%) |
| Asian | 4 (20%) |
| Stage at enrollment* | |
| I/II | 8 (40%) |
| III/IV | 12 (60%) |
| Histology | |
| DLBCL NOS | 16 (80%) |
| DLBCL triple hit | 1 (5%) |
| DLBCL gray zone | 1 (5%) |
| DLBCL T-cell histiocyte-rich | 1 (5%) |
| CD20+ classical Hodgkin lymphoma | 1 (5%) |
| Prior ASCT | 14 (70%) |
| Chemoresponsive disease at transplant | 13 (65%) |
| Prior therapies, median (range) | 4.5 (2-14) |
| Prior radiation therapy | 13 (65%) |
| >20 Gy Radiation | 12 (60%) |
| Prior CAR-T therapy | 4 (20%) |
| Bulky disease (≥5 cm) | 3 (15%) |
| Disease state, pretreatment* | |
| Complete response | 10 (50%) |
| Partial response | 1 (5%) |
| Stable disease | 6 (30%) |
| Progressive disease | 3 (15%) |
| Donor type | |
| Matched related | 10 (50%) |
| Matched unrelated | 10 (50%) |
| Characteristic . | Study population (n = 20) . |
|---|---|
| Age, median (range), y | 52.5 (36-66) |
| Sex | |
| Female | 7 (35%) |
| Male | 13 (65%) |
| Race | |
| White | 16 (80%) |
| Asian | 4 (20%) |
| Stage at enrollment* | |
| I/II | 8 (40%) |
| III/IV | 12 (60%) |
| Histology | |
| DLBCL NOS | 16 (80%) |
| DLBCL triple hit | 1 (5%) |
| DLBCL gray zone | 1 (5%) |
| DLBCL T-cell histiocyte-rich | 1 (5%) |
| CD20+ classical Hodgkin lymphoma | 1 (5%) |
| Prior ASCT | 14 (70%) |
| Chemoresponsive disease at transplant | 13 (65%) |
| Prior therapies, median (range) | 4.5 (2-14) |
| Prior radiation therapy | 13 (65%) |
| >20 Gy Radiation | 12 (60%) |
| Prior CAR-T therapy | 4 (20%) |
| Bulky disease (≥5 cm) | 3 (15%) |
| Disease state, pretreatment* | |
| Complete response | 10 (50%) |
| Partial response | 1 (5%) |
| Stable disease | 6 (30%) |
| Progressive disease | 3 (15%) |
| Donor type | |
| Matched related | 10 (50%) |
| Matched unrelated | 10 (50%) |
NOS, not otherwise specified.
Stage of the patient was determined based on the clinical presentation of their disease before hematopoietic cell transplantation, whereas disease status was based on response to last prior line of therapy before enrollment on study.